The Influence of Peripheral Arterial Disease on Outcomes: a Pooled Analysis of Mortality in Eight Large Randomized Percutaneous Coronary Intervention Trials
Overview
Authors
Affiliations
Objectives: We aimed to evaluate clinical outcomes among peripheral arterial disease (PAD) patients following percutaneous coronary intervention (PCI).
Background: A significant proportion of patients with coronary artery disease undergoing PCI have concomitant PAD, which may be associated with worse outcomes.
Methods: We performed a pooled analysis of 8 randomized PCI trials. We included multicenter PCI trials that compared antiplatelet therapies (EPIC, EPILOG, EPISTENT, RAPPORT, CAPTURE, IMPACT-II, TARGET, and CREDO) and had baseline PAD status recorded. Multivariable analyses were performed with stepwise logistic regression for 7- and 30-day outcomes and Cox regression for 6-month and 1-year events.
Results: In our pooled analysis of 19,867 patients undergoing PCI, 1,602 (8.1%) were previously diagnosed with PAD. Patients with PAD had higher incidences of 7-day death (1.0% vs. 0.4%; p < 0.001) or myocardial infarction (MI) (6.8% vs. 5.6%; p = 0.047), 30-day death (1.7% vs. 0.7%; p < 0.001) or MI (7.4% vs. 6.1%; p = 0.05), 6-month death (4.2% vs. 1.5%; p < 0.001) or MI (9.1%, vs. 7.7%; p = 0.048), and 1-year death (5.0% vs. 2.1%; p < 0.001). There was a trend toward higher major bleeding risk with PAD (4.8% vs. 3.9%; p = 0.06). With multivariable analyses, PAD remains a significant predictor of mortality at 30 days (hazard ratio [HR] 1.67, 95% confidence interval [CI] 1.03 to 2.70; p = 0.039), 6 months (HR 1.76, 95% CI 1.31 to 2.37; p < 0.001), and 1 year (HR 1.46, 95% CI 1.08 to 1.96; p = 0.013).
Conclusions: The presence of PAD is associated with higher rates of post-PCI death and MI, and is an independent predictor of short- and long-term mortality.
Xia Y, Han K, Cheng Y, Wang Z, Gao F, Ma X Rev Cardiovasc Med. 2024; 24(11):332.
PMID: 39076444 PMC: 11272883. DOI: 10.31083/j.rcm2411332.
Gutierrez J, Harrington R, Stone G, Steg P, Gibson C, Hamm C Am Heart J Plus. 2024; 9:100043.
PMID: 38551015 PMC: 10978113. DOI: 10.1016/j.ahjo.2021.100043.
Olinic M, Lazar F, Onea H, Homorodean C, Ober M, Tataru D Life (Basel). 2024; 14(3).
PMID: 38541658 PMC: 10971718. DOI: 10.3390/life14030333.
Gonzalez-Lorenzo O, Franco Pelaez J, Kallmeyer A, Nieto L, Esteban L, Pello A Front Cardiovasc Med. 2024; 11:1305162.
PMID: 38464841 PMC: 10921089. DOI: 10.3389/fcvm.2024.1305162.
Pinxterhuis T, von Birgelen C, Geelkerken R, Doggen C, Menting T, van Houwelingen K Cardiovasc Interv Ther. 2024; 39(2):173-182.
PMID: 38353865 PMC: 10940370. DOI: 10.1007/s12928-024-00986-7.